[email protected]

Summary In this week’s episode of Startup Junkies, hosts Daniel Koonce and Caleb Talley sit down for an engaging conversation with Daniel Schroeder and Brent Reader, co-founders of Peanut Pupper, a startup helping anxious dogs with their CBD products. The conversation explores how Peanut Pupper began, what sets it apart, and how its founders are […]

The post Spark! 2025 Spotlight Series | Kamesha Lindsey appeared first on The Venture Center.

The post Spark! 2025 Spotlight Series | Tameka Riley appeared first on The Venture Center.

BioVentures, in collaboration with the University of Arkansas for Medical Sciences (UAMS), has been awarded a grant from the National Institutes of Health (NIH) to launch the Cancer and Developing Entrepreneurial Technologies (CADET) program. Administered by BioVentures, CADET is designed to equip cancer researchers with the entrepreneurial principles and mentorship needed to translate laboratory discoveries

What’s the problem? Some neurosurgical procedures require patients to remain awake and responsive. These procedures can cause significant anxiety, making it difficult for patients to perform cognitive or motor tasks critical for surgical success.  What does this technology do? This patent covers an immersive distraction apparatus that integrates with a surgical head frame to deliver virtual reality experiences during awake surgeries.

Join us on October 22, from 4–6 PM at the Jack Stephens Spine Institute (12th Floor) for the next UAMS Showcase of Medical Discoveries, focused on UAMS intellectual property and innovations.  The event will feature technologies developed by UAMS researchers and supported through BioVentures, offering a look at discoveries with the potential to improve health

We were excited to host the kickoff meeting for one of our newest startups, OncoRock Therapeutics, right here at BioVentures!   OncoRock is a biotechnology startup dedicated to transforming academic discoveries into impactful cancer treatments. Their capital-efficient model focuses on acquiring promising university assets, de-risking them through preclinical studies and early-phase clinical trials, and then partnering